Atrial Fibrillation Trial, Recruiting NCT04347187 Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT04347187
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with atrial fibrillation (an irregular heartbeat condition) and have a stroke risk score above 1 based on a standard medical scoring system called CHA2DS2-VASc (confirm with trial site)

Who may not be able to join:

  • People who are unwilling or unable to give their written agreement to take part in the study
  • People who have had a serious heart attack (acute coronary syndrome) within the 12 months before joining
  • People with very severe heart failure (classified as the most serious stage, known as NYHA Class IV)
  • People who have had a stroke within the 6 months before joining
  • People with severe liver disease or severe muscle disease
  • People with severe kidney disease or kidney failure, where a specific kidney function measurement (creatinine) is above a certain level
  • People where it would not be possible to contact them or a family member for a follow-up check one year after the study procedure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Elizaveta Panchenko, PhD, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Phone: +79166760695

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Registry
ClinicalTrials.gov
Start date
15 January 2015
Est. completion
31 December 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

composite of major cardiovascular events; composite of any bleeding events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov